Nektar Therapeutics (NKTR) News Today $0.93 -0.01 (-1.35%) (As of 12/20/2024 05:23 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Jonathan Zalevsky Sells 51,115 Shares of Nektar Therapeutics (NASDAQ:NKTR) StockDecember 21 at 8:02 AM | insidertrades.comNektar Therapeutics (NASDAQ:NKTR) Insider Sells $48,048.10 in StockNektar Therapeutics (NASDAQ:NKTR - Get Free Report) insider Jonathan Zalevsky sold 51,115 shares of Nektar Therapeutics stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $0.94, for a total value of $48,048.10. Following the sale, the insider now owns 326,904 shares of the company's stock, valued at approximately $307,289.76. This represents a 13.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.December 20 at 10:29 PM | marketbeat.comInsider Selling: Nektar Therapeutics (NASDAQ:NKTR) CEO Sells 46,995 Shares of StockDecember 20 at 9:09 AM | insidertrades.comNektar Therapeutics (NASDAQ:NKTR) Receives Average Recommendation of "Moderate Buy" from BrokeragesNektar Therapeutics (NASDAQ:NKTR - Get Free Report) has received an average rating of "Moderate Buy" from the six brokerages that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the cDecember 20 at 4:51 AM | marketbeat.comHoward W. Robin Sells 46,995 Shares of Nektar Therapeutics (NASDAQ:NKTR) StockNektar Therapeutics (NASDAQ:NKTR - Get Free Report) CEO Howard W. Robin sold 46,995 shares of the firm's stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $1.01, for a total transaction of $47,464.95. Following the completion of the sale, the chief executive officer now owns 1,195,710 shares in the company, valued at $1,207,667.10. The trade was a 3.78 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.December 19 at 10:30 PM | marketbeat.comNektar Therapeutics CEO Robin Howard sells $131,649 in stockDecember 19 at 9:35 PM | investing.comNektar Therapeutics (NASDAQ:NKTR) & Aravive (NASDAQ:ARAV) Head to Head AnalysisDecember 17, 2024 | americanbankingnews.comResearch Analysts Offer Predictions for NKTR FY2024 EarningsDecember 13, 2024 | americanbankingnews.comPromising Future for Nektar Therapeutics: Innovative Approach in Autoimmune Disease Treatment with RezpegaldesleukinDecember 12, 2024 | markets.businessinsider.comResearch Analysts Issue Forecasts for NKTR FY2024 EarningsNektar Therapeutics (NASDAQ:NKTR - Free Report) - Analysts at HC Wainwright issued their FY2024 earnings per share estimates for Nektar Therapeutics in a report issued on Tuesday, December 10th. HC Wainwright analyst A. He forecasts that the biopharmaceutical company will post earnings of ($0.46)December 12, 2024 | marketbeat.comQ1 Earnings Forecast for NKTR Issued By HC WainwrightDecember 12, 2024 | americanbankingnews.comNektar initiated with a Buy at H.C. WainwrightDecember 11, 2024 | markets.businessinsider.comWhat is HC Wainwright's Estimate for NKTR Q1 Earnings?Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Nektar Therapeutics in a note issued to investors on Tuesday, December 10th. HC Wainwright analyst A. He forecasts that the biopharmaceutical company will posDecember 11, 2024 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Coverage Initiated by Analysts at HC WainwrightHC Wainwright started coverage on shares of Nektar Therapeutics in a research report on Tuesday. They issued a "buy" rating and a $6.50 price objective on the stock.December 10, 2024 | marketbeat.comNektar's NKTR-255 After CD19 CAR-T Therapy Enhances Complete Response In R/R Large B-Cell LymphomaDecember 8, 2024 | markets.businessinsider.comNektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH MeetiDecember 7, 2024 | investing.comNektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH MeetingDecember 7, 2024 | prnewswire.comEventide Asset Management LLC Boosts Holdings in Nektar Therapeutics (NASDAQ:NKTR)Eventide Asset Management LLC boosted its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 24.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 9,400,000 shares of the biopharmaceutical company's stock after purchasing an additioNovember 29, 2024 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Given Consensus Rating of "Moderate Buy" by BrokeragesNektar Therapeutics (NASDAQ:NKTR - Get Free Report) has received an average recommendation of "Moderate Buy" from the five analysts that are currently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and three have issued a buy recommendationNovember 25, 2024 | marketbeat.comGSA Capital Partners LLP Sells 716,698 Shares of Nektar Therapeutics (NASDAQ:NKTR)GSA Capital Partners LLP lessened its stake in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 77.0% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 214,245 shares of the biopharmaceutical company's stock afterNovember 24, 2024 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) CEO Sells $16,440.78 in StockNovember 21, 2024 | insidertrades.comNektar presents preclinical data on NKTR-422 at ACR conferenceNovember 20, 2024 | markets.businessinsider.comNektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) ConvergenceNovember 18, 2024 | prnewswire.comMultiple Catalysts Ahead For Nektar TherapeuticsNovember 15, 2024 | seekingalpha.comDeep Track Capital, LP Reduces Stake in Nektar TherapeuticsNovember 14, 2024 | gurufocus.comNektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price TargetsNovember 10, 2024 | finance.yahoo.comNektar presents late-breaking results from Phase 2 Study of NKTR-255November 9, 2024 | markets.businessinsider.comNektar Therapeutics Reports Stable Q3 Earnings for 2024November 9, 2024 | markets.businessinsider.comNektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial OutlookNovember 9, 2024 | finance.yahoo.comQ3 2024 Nektar Therapeutics Earnings Call TranscriptNovember 8, 2024 | gurufocus.comNektar Therapeutics Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | prnewswire.comNektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual MeetingNovember 7, 2024 | prnewswire.comNektar To Sell Manufacturing Facility In Alabama, Reagent Supply Business To AmpersandNovember 6, 2024 | markets.businessinsider.comNektar Therapeutics Q3 2024 Earnings PreviewNovember 6, 2024 | msn.comNektar Therapeutics to Participate in Upcoming Investor ConferencesNovember 6, 2024 | prnewswire.comNektar to sell its Huntsville, Alabama facility to Ampersand Capital for $90MNovember 5, 2024 | markets.businessinsider.comNektar Therapeutics to sell Alabama facility to AmpersandNovember 5, 2024 | finance.yahoo.comNektar Therapeutics Sells Manufacturing Facility for $90MNovember 5, 2024 | markets.businessinsider.comPiper Sandler Initiates Coverage of Nektar Therapeutics (NKTR) with Overweight RecommendationNovember 5, 2024 | msn.comEczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside PotentialNovember 4, 2024 | benzinga.comNektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in AlabamaNovember 4, 2024 | prnewswire.comNektar Therapeutics (NASDAQ:NKTR) Now Covered by Piper SandlerPiper Sandler began coverage on shares of Nektar Therapeutics in a research note on Monday. They set an "overweight" rating and a $7.00 price target on the stock.November 4, 2024 | marketbeat.comNektar Therapeutics (NKTR) to Release Earnings on ThursdayNektar Therapeutics (NASDAQ:NKTR) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comNektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial MarketsOctober 31, 2024 | prnewswire.comNektar reports positive Phase 1b skin disease study resultsOctober 31, 2024 | investing.comNektar Therapeutics (NASDAQ:NKTR) Given Average Recommendation of "Hold" by BrokeragesShares of Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) have earned an average recommendation of "Hold" from the six ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation andOctober 31, 2024 | marketbeat.comNektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin DiseasesOctober 29, 2024 | prnewswire.comNektar Therapeutics (NASDAQ:NKTR) Short Interest UpdateNektar Therapeutics (NASDAQ:NKTR - Get Free Report) saw a significant drop in short interest during the month of October. As of October 15th, there was short interest totalling 6,040,000 shares, a drop of 17.4% from the September 30th total of 7,310,000 shares. Based on an average daily volume of 1,030,000 shares, the short-interest ratio is presently 5.9 days. Approximately 3.4% of the shares of the company are short sold.October 28, 2024 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Stock Crosses Above Two Hundred Day Moving Average - What's Next?Nektar Therapeutics (NASDAQ:NKTR) Share Price Crosses Above Two Hundred Day Moving Average - Here's What HappenedOctober 22, 2024 | marketbeat.comNektar sees promising phase 1 results of NKTR-255 in B-cell lymphoblastic leukemiaOctober 17, 2024 | msn.com Get Nektar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Email Address Most People Are Dead Wrong. (Ad)Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years. I call it my AI Retirement Playbook. I recommend you check it out now. NKTR Media Mentions By Week NKTR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NKTR News Sentiment▼0.670.60▲Average Medical News Sentiment NKTR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NKTR Articles This Week▼82▲NKTR Articles Average Week Get Nektar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OMER News Today ASMB News Today CPIX News Today LLY News Today JNJ News Today ABBV News Today MRK News Today PFE News Today BMY News Today ZTS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NKTR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
